SOURCE: Active Biotech

February 16, 2006 02:42 ET

Active Biotech Year-end Report January-December 2005

LUND, SWEDEN -- (MARKET WIRE) -- February 16, 2006 --


* Positive results reported for all projects in 2005

* Progress in the mode of action project regarding quinoline substances

* Phase II/III study of ANYARA for renal cancer planned

* Net sales: SEK 9.2 M (69.7)

* Operating loss: SEK 133.2 M (loss: 185.9)

* Loss after tax: SEK 135.4 M (loss: 171.9)

* Loss per share for the period: SEK 3.70 (loss: 4.96)



Copyright © Hugin ASA 2006. All rights reserved.

Contact Information